- Home
- IMRX
as of 01-22-2026 3:46pm EST
$5.33
$0.01
-0.12%
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 366.1M | IPO Year: | 2021 |
| Target Price: | $17.20 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $10.08 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered IMRX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 0.00%
0.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Immuneering Corporation (IMRX)
Brakewood Harold Eugene
Buy
Chief Business Officer
IMRX Jan 16, 2026
Avg Cost/Share
$4.76
Shares
5,250
Total Value
$24,990.00
Owned After
11,050
SEC Form 4
Schall Thomas J.
Buy
Director
IMRX Jan 15, 2026
Avg Cost/Share
$4.67
Shares
21,645
Total Value
$101,041.02
Owned After
74,530
SEC Form 4
Hall Brett Matthew
Buy
CHIEF SCIENTIFIC OFFICER
IMRX Jan 15, 2026
Avg Cost/Share
$4.57
Shares
2,298
Total Value
$10,501.86
Owned After
376,496
SEC Form 4
Neufeld Leah R
Buy
CHIEF PEOPLE OFFICER
IMRX Jan 13, 2026
Avg Cost/Share
$4.15
Shares
2,626
Total Value
$10,905.78
Owned After
25,970
SEC Form 4
Feinberg Peter
Buy
Director
IMRX Jan 12, 2026
Avg Cost/Share
$4.35
Shares
20,000
Total Value
$86,904.00
Owned After
135,441
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Brakewood Harold Eugene | IMRX | Chief Business Officer | Jan 16, 2026 | Buy | $4.76 | 5,250 | $24,990.00 | 11,050 | |
| Schall Thomas J. | IMRX | Director | Jan 15, 2026 | Buy | $4.67 | 21,645 | $101,041.02 | 74,530 | |
| Hall Brett Matthew | IMRX | CHIEF SCIENTIFIC OFFICER | Jan 15, 2026 | Buy | $4.57 | 2,298 | $10,501.86 | 376,496 | |
| Neufeld Leah R | IMRX | CHIEF PEOPLE OFFICER | Jan 13, 2026 | Buy | $4.15 | 2,626 | $10,905.78 | 25,970 | |
| Feinberg Peter | IMRX | Director | Jan 12, 2026 | Buy | $4.35 | 20,000 | $86,904.00 | 135,441 |
Latest Immuneering Corporation News
IMRX Breaking Stock News: Dive into IMRX Ticker-Specific Updates for Smart Investing
Compare IMRX vs Leading Stocks
See how IMRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IMRX Immuneering Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.